BioCentury
ARTICLE | Clinical News

Exact HCC assay significantly better than SOC

June 7, 2018 11:11 PM UTC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test.

The test is the most advanced in Exact's pipeline behind its marketed Cologuard colorectal cancer screening test...